FY2025 · ended Dec 31, 2025 · Revenue $2.49M, -37.1% YoY · Filed Apr 15, 2026
Geovax Labs, Inc. (GOVX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $2.5 million and a net loss of $21.5 million. Free cash flow was -$21.5 million. As of Jun 30, 2026 it held $3.1 million in cash and investments and $323,141 in total debt.
Revenue (TTM)
$0
-100.0% vs year-ago TTM
Net income (TTM)
$-20.43M
+17.7% vs year-ago TTM
Operating cash flow (TTM)
$-18.37M
+32.8% vs year-ago TTM
Free cash flow (TTM)
$-18.37M
+33.0% vs year-ago TTM
EPS
—
Dividend per share
None
Shares outstanding
2.89M
-79.1% vs prior year
Net cash
$2.82M
as of Jun 30, 2026
Operating margin
-869.3%
FY 2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GOVX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Smyrna, GA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 832489
- Former names
- DAUPHIN TECHNOLOGY INC (until Sep 20, 2006)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $2.5M | $4.0M | $0 | $81,526 | $385,501 |
| Operating income | -$21.6M | -$25.1M | -$26.7M | -$14.0M | -$18.7M |
| Net income | -$21.5M | -$25.0M | -$26.0M | -$14.0M | -$18.6M |
| Operating cash flow | -$21.5M | -$24.7M | -$25.2M | -$19.0M | -$11.2M |
| Free cash flow | -$21.5M | -$24.7M | -$25.2M | -$19.2M | -$11.2M |
| Total assets | $6.3M | $8.2M | $9.3M | $31.3M | $11.8M |
| Total liabilities | $2.5M | — | — | $4.7M | $7.4M |
| Stockholders' equity | $3.8M | $5.0M | $5.8M | $26.6M | $4.4M |
| Cash and investments | $3.1M | $5.5M | $6.5M | $27.6M | $11.4M |
| Total debt | $843,170 | — | — | — | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Shareholder vote results
|
Oct 27, 2026 | Oct 27, 2026 |
| 8-K |
Current report
Material agreement, New debt, Change to shareholder rights, Officer or director change, Regulation FD disclosure
|
Oct 27, 2026 | Oct 23, 2026 |
| 8-K |
Current report
Other events
|
Sep 10, 2026 | Sep 10, 2026 |
| 8-K |
Current report
Listing notice
|
Aug 28, 2026 | Aug 27, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Aug 28, 2026 | Aug 25, 2026 |
| 10-Q | Quarterly report | Jul 27, 2026 | Jun 30, 2026 |
All 1000 Geovax Labs, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.